

Pending Claims

95. A therapeutic composition, comprising a first isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:16;

(b) a polypeptide comprising at least part of a sequence as described in (a) above and has an epitope in common therewith; and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith;

wherein said composition can be used to reduce an allergic response to a cat antigen in an individual sensitive to said antigen.

96. A composition according to claim 95 comprising a mixture of said first polypeptides.

101. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:16;

(b) a polypeptide comprising at least a part of a sequence as described in (a) above and has an epitope in common therewith; and

(c) a modified form of a polypeptide as described in (a) or (b) above, which has at least one epitope in common therewith.

102. A polypeptide according claim 101, wherein the polypeptide has a stimulation index of at least approximately 4.0 or a positivity index of at least approximately 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a

population of responding individuals tested multiplies by the percentage of individuals in the population exhibiting a positive response.

103. A polypeptide according to claim 101, produced recombinantly.

104. A polypeptide according to claim 101, produced by chemical synthesis.